| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Hospital & Healthcare Services
|
Compare with Industry peers |
| Website | http://www.invictameditek.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 5.41 Cr. | |
| Earnings per share (EPS) | -0.11 | Trailing Twelve Months Ending 2021-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2021-03 |
| Industry PE | 223.80 | Trailing Twelve Months Ending 2021-03 |
| Book Value / Share | 0.03 | Trailing Twelve Months Ending 2021-03 |
| Price to Book Value | 300.00 | Calculated using Price: 7.50 |
| Dividend Yield | 0.00 | Period Ending 2020-03 |
| No. of Shares Subscribed | 0.72 Cr. | 7,209,041 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Invicta Meditek Limited (Invicta) incorporated in 1992 is a Public Limited company engaged in the manufacture of quality Orthopaedic Implants and Instruments. Invicta Meditek manufacture the quality Orthopaedic Implants and Instruments. Invicta serves the field of Orthopaedics by supplying products for Total Joint Replacement systems, Trauma Implants and Associated Instruments. The product range also includes implants for Hemi-Arthroplasty, all types of Dynamic Compression and round hole plates, Screws with Cortical, Cancellous profiles, special thread sizes and in all diameters (with and without cannulation) and DHS/ DCS systems. The Joint Replacement Systems for Knee, Hip, Shoulder and Ankle are manufactured under license from Endotec Inc., USA. Invicta has established a full-fledged machine shop with sophisticated, state of the art machinery required to meet the challenging, stringent quality requirements of the Orthopaedic implants and the high levels of accuracy required for the instruments used in joint replacement and other critical surgical operations. Invicta lays special emphasis on achieving customer satisfaction by demonstrating the ability to consistently provide products that meet and exceed customer requirements. The Quality Control Department is equipped with the latest tools and instruments maintaining the strict quality standards demanded by the orthopaedic community. Invicta’s product portfolio includes:-Total Joint Replacements for Knee, Hip, Ankle, Shoulder (under license from Endotec Inc., USA) -trauma implants (plates, screws, nails etc) -associated instrumentation Product range of the company includes:
Achievements/ recognition :
|
||
Company Profile
Invicta Meditek Limited (Invicta) incorporated in 1992 is a Public Limited company engaged in the manufacture of quality Orthopaedic Implants and Instruments.
Invicta Meditek manufacture the quality Orthopaedic Implants and Instruments. Invicta serves the field of Orthopaedics by supplying products for Total Joint Replacement systems, Trauma Implants and Associated Instruments. The product range also includes implants for Hemi-Arthroplasty, all types of Dynamic Compression and round hole plates, Screws with Cortical, Cancellous profiles, special thread sizes and in all diameters (with and without cannulation) and DHS/ DCS systems. The Joint Replacement Systems for Knee, Hip, Shoulder and Ankle are manufactured under license from Endotec Inc., USA.
Invicta has established a full-fledged machine shop with sophisticated, state of the art machinery required to meet the challenging, stringent quality requirements of the Orthopaedic implants and the high levels of accuracy required for the instruments used in joint replacement and other critical surgical operations.
Invicta lays special emphasis on achieving customer satisfaction by demonstrating the ability to consistently provide products that meet and exceed customer requirements. The Quality Control Department is equipped with the latest tools and instruments maintaining the strict quality standards demanded by the orthopaedic community.
Invicta’s product portfolio includes:-Total Joint Replacements for Knee, Hip, Ankle, Shoulder (under license from Endotec Inc., USA) -trauma implants (plates, screws, nails etc) -associated instrumentation
Product range of the company includes:
Achievements/ recognition :
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
+9.65% |
| 3 Month |
|
+9.49% |
| 6 Month |
|
+61.29% |
| 1 Year |
|
+88.44% |
| 2 Year |
|
+81.60% |
| 5 Year |
|
+89.87% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | -5.20 | -6.86 | -6.88 | -10.77 | -12.17 | -14.42 | -42.43 | -171.88 | 192.41 | |
| Return on Capital Employed (%) | -5.14 | -6.80 | -6.78 | -10.74 | -12.13 | -14.10 | -20.15 | -2.97 | 11.11 | |
| Return on Assets (%) | -4.40 | -4.86 | -4.10 | -5.95 | -6.02 | -6.25 | -11.92 | -2.40 | 8.89 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||
| Non Curr. Liab. | 1 | 0 | 0 | |||||||
| Curr. Liab. | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | |
| Minority Int. | ||||||||||
| Equity & Liab. | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Non Curr. Assets | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
| Curr. Assets | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 0 | 1 | 2 | |||||||
| Other Income | 0 | |||||||||
| Total Income | 0 | 0 | 1 | 2 | ||||||
| Total Expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -2 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | ||||||||||
| Depreciation | ||||||||||
| Taxation | ||||||||||
| Exceptional Items | ||||||||||
| PAT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Cash Fr. Inv. | ||||||||||
| Cash Fr. Finan. | 0 | 0 | ||||||||
| Net Change | 0 | 0 | 0 | 0 | 0 | |||||
| Cash & Cash Eqvt | 0 | 0 | 0 | 0 |
|
Tue, 06 Jul 2021
Closure of Trading Window This is to inform you that as per Companys Code of Conduct for Prohibition of Insider Trading framed pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015 the Trading Window for dealing in Securities of the Company is closed for all Designated Employees (including Directors) of the Company from 1st July 2021 till end of 48 hours after the declaration of the financial results of the Company for the quarter ended 30th June 2021. All Designated Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of Trading Window. We kindly request you to take on record of the same. |
||||||||||||||
|
Tue, 06 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
|
||||||||||||||
|
Tue, 06 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Pursuant to the Regulation 74(5) of SEBI (Depositories and Participants) Regulation 2018 we hereby enclosed the certificate received from Cameo Corporate Services Limited the registrar and Share transfer agent of our company for the quarter ended 30.06.2021. |
|
No Scans Found |
Equities
M.F.
Sectors